World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
60
Citations
15095
World Ranking
3097
National Ranking
178

Overview

Gilles Peytavin is a researcher affiliated with Claude Bernard University Lyon 1 in France, specializing in medicine with a strong focus on infectious diseases. Their work spans several important subfields, including infectious diseases, virology, epidemiology, hepatology, and neurology.

The researcher has made significant contributions to topics including:

  • HIV/AIDS drug development and treatment
  • HIV/AIDS research and interventions
  • HIV research and treatment
  • COVID-19 clinical research studies
  • SARS-CoV-2 and COVID-19 research
  • Hepatitis C virus research
  • Long-term effects of COVID-19

Among their recent publications are:

  • Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial, 2021, The Lancet Infectious Diseases
  • Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon, 2020, The Lancet HIV
  • An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19, 2021, Clinical Microbiology and Infection
  • Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study, 2022, The Lancet HIV
  • Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives, 2020, Clinical Microbiology and Infection

Peytavin frequently collaborates with other researchers in the field. Notable coauthors include Minh Lê, Jade Ghosn, Diane Descamps, Alpha Diallo, and Quentin Le Hingrat.

The bulk of their scientific publications appear in several key venues, such as:

  • Journal of Antimicrobial Chemotherapy
  • Clinical Infectious Diseases
  • Médecine et Maladies Infectieuses Formation
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Clinical Microbiology and Infection

The overall body of work indicates a strong research focus on clinical infectious diseases, with particular attention given to viral infections affecting global health, including HIV/AIDS and COVID-19. Their multidisciplinary approach bridges clinical trials, drug resistance studies, and diagnostic marker identification within these domains.

Best Publications

  • On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection

    Abstr Act;C. Capitant;B. Spire;G. Pialoux

  • Autoantibodies neutralizing type I IFNs are present in ~ 4% of uninfected individuals over 70 years old and account for ~ 20% of COVID-19 deaths.

    Paul Bastard;Adrian Gervais;Adrian Gervais;Tom Le Voyer;Tom Le Voyer;Jérémie Rosain;Jérémie Rosain

  • Mechanisms of Virologic Failure in Previously Untreated HIV-Infected Patients From a Trial of Induction-Maintenance Therapy

    D Descamps;P Flandre;V Calvez;G Peytavin

  • Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study

    Jean-Michel Molina;Jean-Michel Molina;Isabelle Charreau;Bruno Spire;Laurent Cotte

  • Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.

    Ana Canestri;Franæois-Xavier Lescure;Stephane Jaureguiberry;Antoine Moulignier

  • Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro

    Isabelle Malet;Olivier Delelis;Marc-Antoine Valantin;Brigitte Montes

  • Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial

    Christian Laurent;Charles Kouanfack;Sinata Koulla-Shiro;Nathalie Nkoué

  • Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial.

    Jean-Luc Meynard;Muriel Vray;Laurence Morand-Joubert;Esther Race

  • Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C.

    Aude Desnoyer;Dan Pospai;Minh Patrick Lê;Anne Gervais

  • Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136.

    Christine Katlama;Marc A Valantin;Michele Algarte-Genin;Claudine Duvivier

  • HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report

    Pierre Frange;Pierre Frange;Albert Faye;Véronique Avettand-Fenoël;Véronique Avettand-Fenoël;Erianna Bellaton

  • Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial

    Anani Badje;Raoul Moh;Delphine Gabillard;Calixte Guéhi

  • Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.

    Christophe Piketty;Esther Race;Philippe Castiel;Laurent Belec

  • Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma.

    Anne-Geneviève Marcelin;Roland Tubiana;Sidonie Lambert-Niclot;Gilles Lefebvre

  • Evaluation of the Patient Medication Adherence Questionnaire As a Tool for Self-Reported Adherence Assessment in HIV-Infected Patients on Antiretroviral Regimens

    Michel Duong;Lionel Piroth;Michèle Grappin;Fabien Forte

  • In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors

    Delphine Desbois;Bénédicte Roquebert;Gilles Peytavin;Florence Damond

  • HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro

    B. Roquebert;B. Roquebert;F. Damond;G. Collin;S. Matheron

  • Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men.

    Jade Ghosn;Marie-Laure Chaix;Gilles Peytavin;Elisabeth Rey

  • Value of Patient Self-Report and Plasma Human Immunodeficiency Virus Protease Inhibitor Level as Markers of Adherence to Antiretroviral Therapy: Relationship to Virologic Response

    Michel Duong;Lionel Piroth;Gilles Peytavin;Fabien Forte

  • Genotypic Inhibitory Quotient as Predictor of Virological Response to Ritonavir-Amprenavir in Human Immunodeficiency Virus Type 1 Protease Inhibitor-Experienced Patients

    Anne-Geneviève Marcelin;Claire Lamotte;Constance Delaugerre;Nadine Ktorza

  • Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors.

    Bénédicte Roquebert;Isabelle Malet;Marc Wirden;Roland Tubiana

Frequent Co-Authors

Christine Katlama
Christine Katlama Sorbonne University
Vincent Calvez
Vincent Calvez Centre national de la recherche scientifique, CNRS
Constance Delaugerre
Constance Delaugerre Université Paris Cité
Françoise Brun-Vézinet
Françoise Brun-Vézinet Université Paris Cité
Anne-Geneviève Marcelin
Anne-Geneviève Marcelin Sorbonne University
Sophie Matheron
Sophie Matheron Université Paris Cité
Jade Ghosn
Jade Ghosn Hôpital Bichat - Claude-Bernard (Hôpitaux Universitaires Paris Nord Val de Seine)
Gilles Pialoux
Gilles Pialoux Tenon Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring microbiology opens doors to diverse career paths, some of which may intersect with other healthcare and scientific fields. For those interested in expanding their expertise, becoming a certified child life specialist salary professional offers a rewarding option that combines science with patient support and advocacy.

Many prospective students may wonder about educational opportunities available despite past challenges. Programs highlighted in what can a felon go to college for provide insight into accessible online degrees, ensuring second chances to those passionate about science and healthcare careers.

For microbiology graduates interested in holistic and integrative healthcare, training to become a functional medicine nurse can broaden clinical skills and promote patient-centered care.

Alternatively, specializing in medical data management through a professional coder certification offers a vital role in the healthcare system with strong job prospects and flexibility.

Each of these pathways complements a foundation in microbiology, offering varied and impactful career options in healthcare and beyond.

Best Scientists Citing Gilles Peytavin

Trending Scientists

Recently Published Articles